Halozyme Therapeutics HALO EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Based on trailing twelve months.
The official record: Halozyme Therapeutics’s 10-Q, filed November 3, 2025, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's EBITDA margin?
- Halozyme Therapeutics (HALO) reported EBITDA margin of 60.2% in Q3 2025.
- How has Halozyme Therapeutics's EBITDA margin changed year-over-year?
- Halozyme Therapeutics's EBITDA margin increased by 17.0% year-over-year, from 51.5% to 60.2%.
- What is the long-term trend for Halozyme Therapeutics's EBITDA margin?
- Over 4 years (2020 to 2024), Halozyme Therapeutics's EBITDA margin has grown at a 0.1% compound annual growth rate (CAGR), from 55.1% to 55.3%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.